Cargando…

Sensitization of dural afferents underlies migraine-related behavior following meningeal application of interleukin-6 (IL-6)

BACKGROUND: Migraine headache is one of the most common neurological disorders, but the pathophysiology contributing to migraine is poorly understood. Intracranial interleukin-6 (IL-6) levels have been shown to be elevated during migraine attacks, suggesting that this cytokine may facilitate pain si...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Jin, Melemedjian, Ohannes K, Price, Theodore J, Dussor, Gregory
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3274468/
https://www.ncbi.nlm.nih.gov/pubmed/22273495
http://dx.doi.org/10.1186/1744-8069-8-6
_version_ 1782223074160017408
author Yan, Jin
Melemedjian, Ohannes K
Price, Theodore J
Dussor, Gregory
author_facet Yan, Jin
Melemedjian, Ohannes K
Price, Theodore J
Dussor, Gregory
author_sort Yan, Jin
collection PubMed
description BACKGROUND: Migraine headache is one of the most common neurological disorders, but the pathophysiology contributing to migraine is poorly understood. Intracranial interleukin-6 (IL-6) levels have been shown to be elevated during migraine attacks, suggesting that this cytokine may facilitate pain signaling from the meninges and contribute to the development of headache. METHODS: Cutaneous allodynia was measured in rats following stimulation of the dura with IL-6 alone or in combination with the MEK inhibitor, U0126. The number of action potentials and latency to the first action potential peak in response to a ramp current stimulus as well as current threshold were measured in retrogradely-labeled dural afferents using patch-clamp electrophysiology. These recordings were performed in the presence of IL-6 alone or in combination with U0126. Association between ERK1 and Nav1.7 following IL-6 treatment was also measured by co-immunoprecipitation. RESULTS: Here we report that in awake animals, direct application of IL-6 to the dura produced dose-dependent facial and hindpaw allodynia. The MEK inhibitor U0126 blocked IL-6-induced allodynia indicating that IL-6 produced this behavioral effect through the MAP kinase pathway. In trigeminal neurons retrogradely labeled from the dura, IL-6 application decreased the current threshold for action potential firing. In response to a ramp current stimulus, cells treated with IL-6 showed an increase in the numbers of action potentials and a decrease in latency to the first spike, an effect consistent with phosphorylation of the sodium channel Nav1.7. Pretreatment with U0126 reversed hyperexcitability following IL-6 treatment. Moreover, co-immunoprecipitation experiments demonstrated an increased association between ERK1 and Nav1.7 following IL-6 treatment. CONCLUSIONS: Our results indicate that IL-6 enhances the excitability of dural afferents likely via ERK-mediated modulation of Nav1.7 and these responses contribute to migraine-related pain behavior in vivo. These data provide a cellular mechanism by which IL-6 in the meninges causes sensitization of dural afferents therefore contributing to the pathogenesis of migraine headache.
format Online
Article
Text
id pubmed-3274468
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32744682012-02-08 Sensitization of dural afferents underlies migraine-related behavior following meningeal application of interleukin-6 (IL-6) Yan, Jin Melemedjian, Ohannes K Price, Theodore J Dussor, Gregory Mol Pain Research BACKGROUND: Migraine headache is one of the most common neurological disorders, but the pathophysiology contributing to migraine is poorly understood. Intracranial interleukin-6 (IL-6) levels have been shown to be elevated during migraine attacks, suggesting that this cytokine may facilitate pain signaling from the meninges and contribute to the development of headache. METHODS: Cutaneous allodynia was measured in rats following stimulation of the dura with IL-6 alone or in combination with the MEK inhibitor, U0126. The number of action potentials and latency to the first action potential peak in response to a ramp current stimulus as well as current threshold were measured in retrogradely-labeled dural afferents using patch-clamp electrophysiology. These recordings were performed in the presence of IL-6 alone or in combination with U0126. Association between ERK1 and Nav1.7 following IL-6 treatment was also measured by co-immunoprecipitation. RESULTS: Here we report that in awake animals, direct application of IL-6 to the dura produced dose-dependent facial and hindpaw allodynia. The MEK inhibitor U0126 blocked IL-6-induced allodynia indicating that IL-6 produced this behavioral effect through the MAP kinase pathway. In trigeminal neurons retrogradely labeled from the dura, IL-6 application decreased the current threshold for action potential firing. In response to a ramp current stimulus, cells treated with IL-6 showed an increase in the numbers of action potentials and a decrease in latency to the first spike, an effect consistent with phosphorylation of the sodium channel Nav1.7. Pretreatment with U0126 reversed hyperexcitability following IL-6 treatment. Moreover, co-immunoprecipitation experiments demonstrated an increased association between ERK1 and Nav1.7 following IL-6 treatment. CONCLUSIONS: Our results indicate that IL-6 enhances the excitability of dural afferents likely via ERK-mediated modulation of Nav1.7 and these responses contribute to migraine-related pain behavior in vivo. These data provide a cellular mechanism by which IL-6 in the meninges causes sensitization of dural afferents therefore contributing to the pathogenesis of migraine headache. BioMed Central 2012-01-24 /pmc/articles/PMC3274468/ /pubmed/22273495 http://dx.doi.org/10.1186/1744-8069-8-6 Text en Copyright ©2012 Yan et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Yan, Jin
Melemedjian, Ohannes K
Price, Theodore J
Dussor, Gregory
Sensitization of dural afferents underlies migraine-related behavior following meningeal application of interleukin-6 (IL-6)
title Sensitization of dural afferents underlies migraine-related behavior following meningeal application of interleukin-6 (IL-6)
title_full Sensitization of dural afferents underlies migraine-related behavior following meningeal application of interleukin-6 (IL-6)
title_fullStr Sensitization of dural afferents underlies migraine-related behavior following meningeal application of interleukin-6 (IL-6)
title_full_unstemmed Sensitization of dural afferents underlies migraine-related behavior following meningeal application of interleukin-6 (IL-6)
title_short Sensitization of dural afferents underlies migraine-related behavior following meningeal application of interleukin-6 (IL-6)
title_sort sensitization of dural afferents underlies migraine-related behavior following meningeal application of interleukin-6 (il-6)
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3274468/
https://www.ncbi.nlm.nih.gov/pubmed/22273495
http://dx.doi.org/10.1186/1744-8069-8-6
work_keys_str_mv AT yanjin sensitizationofduralafferentsunderliesmigrainerelatedbehaviorfollowingmeningealapplicationofinterleukin6il6
AT melemedjianohannesk sensitizationofduralafferentsunderliesmigrainerelatedbehaviorfollowingmeningealapplicationofinterleukin6il6
AT pricetheodorej sensitizationofduralafferentsunderliesmigrainerelatedbehaviorfollowingmeningealapplicationofinterleukin6il6
AT dussorgregory sensitizationofduralafferentsunderliesmigrainerelatedbehaviorfollowingmeningealapplicationofinterleukin6il6